DaVita Inc. (NYSE:DVA) Given Consensus Rating of “Hold” by Brokerages

Shares of DaVita Inc. (NYSE:DVA) have earned an average recommendation of “Hold” from the eight research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $221.75.

A number of equities research analysts have commented on the company. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Barclays lifted their price target on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. TD Cowen upgraded shares of DaVita from a “hold” rating to a “buy” rating and upped their price objective for the stock from $201.00 to $220.00 in a report on Friday, August 7th. Oppenheimer set a $220.00 price objective on shares of DaVita in a research note on Friday, August 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th.

DaVita Trading Up 0.0%

Shares of NYSE DVA opened at $180.72 on Monday. The firm has a market capitalization of $11.53 billion, a P/E ratio of 14.79, a P/E/G ratio of 0.47 and a beta of 0.88. The firm’s 50-day moving average price is $211.96 and its 200-day moving average price is $183.37. DaVita has a 1-year low of $101.00 and a 1-year high of $247.49.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. During the same period last year, the business posted $2.95 EPS. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts forecast that DaVita will post 14.57 EPS for the current year.

Insider Transactions at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On DaVita

Several institutional investors have recently bought and sold shares of DVA. Berkshire Hathaway Inc bought a new position in DaVita during the 2nd quarter valued at $6,425,269,000. California State Teachers Retirement System grew its stake in shares of DaVita by 18,932.5% in the 2nd quarter. California State Teachers Retirement System now owns 8,610,866 shares of the company’s stock worth $1,915,745,000 after acquiring an additional 8,565,623 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of DaVita in the second quarter valued at about $547,520,000. Invesco Ltd. lifted its position in shares of DaVita by 2.0% during the third quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after purchasing an additional 32,358 shares in the last quarter. Finally, Morgan Stanley lifted its position in shares of DaVita by 5.1% during the fourth quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock valued at $167,807,000 after purchasing an additional 71,156 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.